Effects of Aranidipine, a Novel Calcium Channel Blocker, on Mechanical Responses of the Isolated Rat Portal Vein: Comparison with Typical Calcium Channel Blockers and Potassium Channel Openers
- 1 February 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 29 (2) , 209-215
- https://doi.org/10.1097/00005344-199702000-00009
Abstract
We investigated the effects of aranidipine, a dihydropyridine-type Ca2+ channel blocker, on contractile responses to KCl and spontaneous contractions in isolated rat portal veins in comparison with those of the Ca2+ channel blockers, nifedipine, nicardipine, nitrendipine, diltiazem, and verapamil, and of the K+ channel openers, cromakalim and nicorandil. All the Ca2+ channel blockers concentration-dependently inhibited contractions induced by KCl. Interestingly, aranidipine was more potent against the low K+ (20 mM)-induced contraction than the high K+ (80 mM)-induced contraction, whereas the other Ca2+ channel blockers were equally potent against contractions induced by either concentration of KCl. Cromakalim and nicorandil were effective only on the low K(+)-induced contraction. In addition, all the Ca2+ channel blockers and the K+ channel openers tested inhibited the amplitude of spontaneous contractions of isolated rat portal vein. Tetraethylammonium (TEA), a classic K+ channel blocker, significantly attenuated the effect of aranidipine but not of other Ca2+ channel blockers on the spontaneous contractions. The cromakalim-induced inhibition of spontaneous contractions was antagonized by TEA. Thus aranidipine was found to be different from the typical Ca2+ channel blockers and in part similar to the K+ channel openers in inhibiting mechanical responses of isolated rat portal vein, suggesting that activation of K+ channels may in part in part be involved in the aranidipine-induced vasodilation.Keywords
This publication has 23 references indexed in Scilit:
- Aranidipine (MPC‐1304), a New Dihydropyridine Calcium Antagonist: A Review of Its Antihypertensive ActionCardiovascular Drug Reviews, 1996
- MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating actionEuropean Journal of Pharmacology, 1993
- Cardiovascular Profile of MPC-1304, a Novel Dihydropyridine Calcium AntagonistJournal of Cardiovascular Pharmacology, 1993
- Calcium entry blocking activities of MPC-1304 and of its enantiomers and metabolitesEuropean Journal of Pharmacology, 1993
- Effects of imidazoline-related compounds on the mechanical response to nicorandil in the rat portal veinEuropean Journal of Pharmacology, 1992
- MPC-1304, a novel calcium entry blocker, inhibits vasospasm induced by 3,4-diaminopyridine in isolated canine coronary arteriesEuropean Journal of Pharmacology, 1990
- Effect of the K+ efflux stimulating vasodilator BRL 34915 on 86Rb+ efflux and spontaneous activity in guinea‐pig portal veinBritish Journal of Pharmacology, 1987
- Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal veinBritish Journal of Pharmacology, 1986
- The effects of BRL 34915 and nicorandil on electrical and mechanical activity and on 86Rb efflux in rat blood vesselsBritish Journal of Pharmacology, 1986
- Synthesis of asymmetric 4-aryl-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylates with vasodilating and antihypertensive activities.CHEMICAL & PHARMACEUTICAL BULLETIN, 1986